SCHEMBL264790

SCHEMBL264790

O=C(O)CN(Cc1ccccc1)c1ccc(F)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.52
NR3C1 P04150 1/20 0.49
CNR2 P34972 2/20 0.48
CNR1 P21554 1/20 0.48
CYP2C19 P33261 1/20 0.47
SLC6A2 P23975 1/20 0.47
SLC6A4 P31645 1/20 0.47
SLC6A3 Q01959 1/20 0.47
NR1H2 P55055 1/20 0.46
NR1H3 Q13133 1/20 0.46
CRHBP P24387 1/20 0.45
CRHR2 Q13324 1/20 0.45
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
RAB9A P51151 1/20 0.45
TSHR P16473 1/20 0.44
GRIA2 P42262 1/20 0.44
TAS2R14 Q9NYV8 1/20 0.43
KEAP1 Q14145 1/20 0.43
NFE2L2 Q16236 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5189401 0.88 TSHR (0.57) PTPN1NR3C1CNR2CYP2C19NR1H2
SCHEMBL4142849 0.84 TDP1 (0.42) PTPN1KEAP1NFE2L2
SCHEMBL28565303 0.83 CYP2C19 (0.71) NR3C1CNR2CNR1CYP2C19CRHBP
SCHEMBL10906279 0.83 NR3C1 (0.49) PTPN1NR3C1CNR2CYP2C19NR1H2
SCHEMBL8001528 0.80 EGFR (0.44) PTPN1CNR2CNR1KMT2AMEN1
SCHEMBL4282268 0.80 ALDH1A1 (0.44) PTPN1NR3C1CRHBPCRHR2KMT2A
SCHEMBL1932004 0.80 NR1H4 (0.55) NR3C1CYP2C19NR1H2NR1H3KMT2A
SCHEMBL6560868 0.80 NR3C1 (0.56) NR3C1CNR2CNR1RAB9AKEAP1
SCHEMBL9512802 0.78 NR3C1 (0.48) PTPN1NR3C1CNR2CYP2C19NR1H2
SCHEMBL10833174 0.78 TSPO (0.57) NR3C1CYP2C19SLC6A2SLC6A3KEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009001203-A2 AN IMPROVED PROCESS FOR THE PREPARATION OF APREPITANT ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) 2008-12-31 WO claimed
US-8133994-B2 Preparation of aprepitant DR. REDDY'S LABORATORIES LTD. (IN) 2012-03-13 US disclosed
US-20110094321-A1 PREPARATION OF APREPITANT DR. REDDY'S LABORATORIES LIMITED (IN) 2011-04-28 US disclosed
WO-2010092591-A2 NOVEL CRYSTALLINE POLYMORPHS OF 5-[[(2R,3S)-2-[(1R)-1-[3,5- BIS(TRIFLUOROMETHYL) PHENYL] ETHOXY]-3-(4-FLUOROPHENYL)-4-MORPHOLINYL]METHYL]-1,2- DIHYDRO-3H-1,2,4-TRIAZOL-3-ONE AND PROCESS FOR PREPARATION THEREOF USV LIMITED (IN) 2010-08-19 WO disclosed
WO-2009001203-A3 AN IMPROVED PROCESS FOR THE PREPARATION OF APREPITANT ORCHID CHEMICALS & PHARM LTD (IN) 2009-02-26 WO disclosed
WO-2009001203-A2 AN IMPROVED PROCESS FOR THE PREPARATION OF APREPITANT ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) 2008-12-31 WO disclosed
WO-2009001203-A2 AN IMPROVED PROCESS FOR THE PREPARATION OF APREPITANT ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) 2008-12-31 WO disclosed
EP-1942734-A2 PREPARATION OF APREPITANT Dr. Reddy's Laboratories Ltd. (IN) 2008-07-16 EP disclosed
EP-1462450-B1 Substituted morpholine derivatives and their use as therapeutic agents MERCK SHARP & DOHME (GB) 2007-06-13 EP disclosed
WO-2007044829-A2 PREPARATION OF APREPITANT DR. REDDY'S LABORATORIES LTD. (IN) 2007-04-19 WO disclosed
EP-0799056-A1 USE OF A TACHYKININ ANTAGONIST AND AN OPIOID ANALGESIC MERCK SHARP & DOHME LTD. (GB) 1997-10-08 EP disclosed
EP-0777659-A1 MORPHOLINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS MERCK SHARP & DOHME LTD. (GB) 1997-06-11 EP disclosed
US-5612337-A ANALGESIC COMPOUNDS FOR PRODRUGS MERCK SHARP & DOHME LIMITED (GB) 1997-03-18 US disclosed
US-5610159-A N-oxides of morpholine derivatives and their use as therapeutic agents MERCK SHARP & DOHME LIMITED (GB) 1997-03-11 US disclosed
EP-0758329-A1 MORPHOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF TACHIKININS MERCK SHARP & DOHME LTD. (GB) 1997-02-19 EP disclosed
WO-1997002824-A1 USE OF A TACHYKININ ANTAGONIST AND A MUSCARINIC ANTAGONIST AND/OR AN ANTIHISTAMINE TO TREAT MOTION SICKNESS MERCK SHARP & DOHME LIMITED (GB) 1997-01-30 WO disclosed
WO-1996029328-A1 MORPHOLINE DERIVATIVES, COMPOSITIONS CONTAINING THEM AND THEIR USE AS THERAPEUTIC AGENTS MERCK SHARP & DOHME LIMITED (GB) 1996-09-26 WO disclosed
WO-1996020009-A1 USE OF A TACHYKININ ANTAGONIST AND AN OPIOID ANALGESIC MERCK SHARP & DOHME LIMITED (GB) 1996-07-04 WO disclosed
WO-1996005181-A1 MORPHOLINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS MERCK SHARP & DOHME LIMITED (GB) 1996-02-22 WO disclosed
WO-1995030674-A1 MORPHOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF TACHIKININS MERCK SHARP & DOHME LIMITED (GB) 1995-11-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110094321-A1 PREPARATION OF APREPITANT KIT, CPA3, CMA1 PTPN1 4084/4885NR3C1 969/4885CNR2 349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.